TherapeuticsMD
TXMD
38 hedge funds and large institutions have $5.49M invested in TherapeuticsMD in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 8 closing their positions.
343% more call options, than puts
Call options by funds: $31K | Put options by funds: $7K
2.36% less ownership
Funds ownership: 31.92% → 29.57% (-2.4%)
12% less funds holding
Funds holding: 43 → 38 (-5)
29% less capital invested
Capital invested by funds: $7.73M → $5.49M (-$2.24M)
45% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 11
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Clearline Capital
New York
|
+$204K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$29K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$21.6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.83K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.63K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CHAM
Clear Harbor Asset Management
Stamford,
Connecticut
|
-$59.1K |
| 2 |
PCG
Prosperity Consulting Group
Owings Mills,
Maryland
|
-$56.1K |
| 3 |
Renaissance Technologies
New York
|
-$31K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$23.3K |
| 5 |
BlackRock
New York
|
-$21.5K |
TXMD Hedge Fund Activity: Q2 2024 in Review
38 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q2 2024, worth a combined $5.49M — down 29% from $7.73M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of TXMD and 3 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 6 added.
The largest buyer was Clearline Capital, adding an estimated $204K. The largest seller was Clear Harbor Asset Management, exiting entirely with an estimated $59.1K sold.
- 38 institutional investors held TherapeuticsMD (TXMD) as of Q2 2024, down from 43 in Q1 2024.
- Funds reported $5.49M of TherapeuticsMD stock for Q2 2024, down 29% quarter-over-quarter.
- 3 funds opened new TherapeuticsMD positions in Q2 2024 and 8 closed out, a net change of -5 holders.
- The largest TherapeuticsMD buyer in Q2 2024 was Clearline Capital, an estimated $204K added.
- The largest TherapeuticsMD seller in Q2 2024 was Clear Harbor Asset Management, an estimated $59.1K sold.
Based on aggregated 13F filings for Q2 2024.